InflaRx N.V. (IFRX) Stock Score, Valuation & Financial Research
InflaRx N.V. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 16/100.
Quick answer for IFRX
InflaRx N.V. currently has a Wall Street Score of 16/100. The stored market price is $2.04. Its financial score is 12/100. Its valuation score is 0/100. The latest WSS change is +2.7 points. These figures are a research snapshot, not a buy or sell recommendation.
What InflaRx N.V. does
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and
IFRX financial snapshot
- Wall Street Score:
- 16/100
- Current price:
- $2.04
- Market capitalization:
- $300.5M
- Revenue:
- $-12K
- Net income:
- $-45.1M
- Free cash flow:
- $-39.2M
- Cash:
- $169.0M
- Total debt:
- $960K
- EPS:
- -0.31
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is -1.3%.
- Free cash flow is $-39.2M, showing cash burn in the current stored period.
- The balance sheet shows $169.0M of cash versus $960K of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +2.7 points: IFRX increased 2.7 points because Revenue improved by 20 points, Asset improved by 6.6 points, Buffett improved by 5 points.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research IFRX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.